Omeza, LLC is investigating the efficacy of its OCM™ products in combination with standard of care for treating diabetic foot ulcers, a significant market with increasing prevalence due to the rising incidence of diabetes. The trial's completion and results could position Omeza favorably in the wound care market, particularly against established products like Apligraf® and Dermagraft®. The combination therapy approach may enhance treatment outcomes, potentially leading to partnerships or acquisitions by larger pharmaceutical companies focused on diabetes-related complications. Diligence should focus on the competitive landscape, reimbursement pathways, and regulatory considerations, especially given the FDA's oversight of the investigational products.